At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 446 enrolled
Drug / intervention
Remimazolam +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in Patients Undergoing Bronchoscopy
In Brief
A Phase 3 clinical trial evaluating Remimazolam, Placebo, and 1 other intervention for Bronchoscopy. Completed, enrolled 446 participants across 14 sites.
Detailed Summary
A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open label arm for midazolam, in patients undergoing a bronchoscopy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchoscopy
CountriesUnited States
CollaboratorsPremier Research
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartApr 2015
Primary CompletionMar 2017
Study CompletionMar 2017
TodayJul 2026
First PostedNov 21, 2014
Enrollment StartApr 1, 2015
Primary CompletionMar 1, 2017
Study CompletionMar 13, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.6 years ago
Interventions
Remimazolamdrug
For induction and maintenance of sedation
Placebodrug
Inactive control arm
Midazolamdrug
For induction and maintenance of sedation